Orca Bio

“And if you think of the cell as the actual active ingredient of the medicine, the actual medicine is a cell. What you're seeing there is that the, that, that the medicine is self manufacturing within your body and expanding, right? You could never do that with…”

“If you look at a regular medicine from the moment you get the raw material until you ship it to the factory, you build the pills and then you ship, you have the whole distribution network and all the warehousing until it gets to the hospital and ultimately get…”

“And I think the, you know, ultimately, if this keeps progressing the way that we've seen it so far, there's no reason why you couldn't be helping tens of millions of patients.”

“So we have a whole stack of technologies that the technology you mentioned is sort of the accelerator to be able to broaden it out to really huge numbers of patients, where we're basically using lasers and light to move cells around and sort them, and, That ca…”

“Well, we'll see, but the data so far suggests that we can bring it down to practically zero, right? Zero transplant related mortalities.”

“Because you have to condense all of the regular payments that you do when you take a pill. You might take a pill for many years. You have to condense them all into one payment because at the end of the day, this is a single dose curative medicine.”

“We recently actually just got clearance from the FDA to begin clinical trials with multiple sclerosis patients with our second gen product, OrcaQ.”

“We treated about 400 or so folks with a couple of different products that we have in the clinic right now.”

“There's really no medication that stops the progress there.”